

# USING EDUCATION TO HIGHLIGHT THE Role of Biosimilars in Value-Based Care

## 01 Background

- + Biosimilars offer cost-saving advantages, and can help maintain clinical efficacy, both of which are key components of patient care.
- + Clinicians and business owners must understand the limitations and opportunities that exist with biosimilars.
- + There are clinical, ease of use and economic barriers to overcome to achieve adoption of biosimilars.

## 02 Objective

To educate physician leaders, pharmacists and providers in the background and availability of biosimilars to enhance value-based care

## 03 Methods

- + An educational program presented online at a national conference convened to educate providers, pharmacists, nurses and others who serve oncology patients across the country
- + Survey questions to assess changes in healthcare provider knowledge and understanding of the role of biosimilars

## 04 Results

- + More than half of the participants were PharmDs, registered pharmacists or pharmacy technicians.
- + In the pre-assessment survey, just over 70% of participants correctly identified what a biologic was, and nearly half correctly identified the requirement that a biosimilar must demonstrate to be given an FDA designation of "interchangeable."

- + During the program, more than half the participants knew that no biosimilar to date has been given an interchangeability designation.
- + Although fewer people responded to the post-assessment survey, more than 66% of participants correctly identified what a biologic was, and more than half correctly identified the requirement that a biosimilar must demonstrate to be given an FDA designation of "interchangeable."

## 05 Conclusions

There is awareness of biosimilars in general among healthcare professionals, and continued education on the topic can help correct assumptions and misinformation and foster a better understanding of the use of biosimilars in value-based care.

## 06 Limitations

Small sample limits generalizability.

## 07 References

1. FDA. Biosimilars. Available at: <https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars> Accessed April 21, 2020.
2. McCamish M, Pakulski J, Sattler C, Woollett G. Toward interchangeable biologics. *Clin Pharmacol Ther.* 2015;97(3):215-217.
3. Rugo HS, Rifkin RM, Declerck P, Bair AH, Morgan G. Demystifying biosimilars: development, regulation and clinical use. *Future Oncol.* 2019;15(7):777-790.

Created by Premier Inc.  
 Authored by Robert Rifkin, MD; Kashyap Patel, MD

**SURVEY Results:**  
 (Percentages rounded to whole numbers)

### Biosimilars offer cost-saving advantages, and can help maintain clinical efficacy.


#### Biosimilar Product

A biosimilar is a biological product that is highly similar and has no clinically meaningful differences from an existing FDA-approved reference product.

#### Interchangeable Product


An interchangeable product is a biosimilar product that meets additional requirements.

#### Demographics of Online Attendees




#### Q & A

Q. A biosimilar is:



Q. What must a biosimilar demonstrate in order to be given the designation of being interchangeable by the US FDA?



Q. Interchangeability has been granted for which of the following biosimilars?

